462 A randomised open-label phase I/II study adding ONCOS-102 to pemetrexed/cisplatin in patients with unresectable malignant pleural mesothelioma – 24 month survival data

462 A randomised open-label phase I/II study adding ONCOS-102 to pemetrexed/cisplatin in patients with unresectable malignant pleural mesothelioma – 24 month survival data

Bibliographic Details
Main Authors:	Magnus Jaderberg, Victor Levitsky, Luis Paz-Ares, Lukasz Kuryk, Nicolas Isambert, Susana Cedres, Charles Ricordel, Santiago Ponce Aix, Anne-Sophie Moller, Sylvia Vetrhus
Format:	Article
Language:	English
Published:	BMJ Publishing Group 2021-11-01
Series:	Journal for ImmunoTherapy of Cancer

Similar Items

361 A randomised open-label phase I/II study adding ONCOS-102 to pemetrexed/cisplatin in patients with unresectable malignant pleural mesothelioma – 12 month analysis of biomarkers and clinical outcomes
by: Magnus Jaderberg, et al.
Published: (2020-11-01)

ONCOS-102 plus pemetrexed and platinum chemotherapy in malignant pleural mesothelioma: a randomized phase 2 study investigating clinical outcomes and the tumor microenvironment
by: Magnus Jaderberg, et al.
Published: (2023-09-01)

368 Consistent pattern of immune activation induced by oncolytic adenovirus ONCOS-102 across diverse types of solid tumors
by: Magnus Jaderberg, et al.
Published: (2021-11-01)

Combination of immunogenic oncolytic adenovirus ONCOS-102 with anti-PD-1 pembrolizumab exhibits synergistic antitumor effect in humanized A2058 melanoma huNOG mouse model
by: Lukasz Kuryk, et al.
Published: (2019-02-01)

JME-001 phase II trial of first-line combination chemotherapy with cisplatin, pemetrexed, and nivolumab for unresectable malignant pleural mesothelioma
by: Nobukazu Fujimoto, et al.
Published: (2021-10-01)

Feasibility of Tumor Treating Fields with Pemetrexed and Platinum-Based Chemotherapy for Unresectable Malignant Pleural Mesothelioma: Single-Center, Real-World Data
by: Tugce Kutuk, et al.
Published: (2022-04-01)

Analysis of the Efficacy of Pemetrexed Maintenance Therapy in Patients with  Malignant Pleural Mesothelioma
by: Xiaomei ZENG, et al.
Published: (2022-01-01)

Upregulation of Thymidylate Synthase Induces Pemetrexed Resistance in Malignant Pleural Mesothelioma
by: Yuzo Sato, et al.
Published: (2021-09-01)

Antagonist of Growth Hormone-Releasing Hormone Potentiates the Antitumor Effect of Pemetrexed and Cisplatin in Pleural Mesothelioma
by: Iacopo Gesmundo, et al.
Published: (2022-09-01)

In Vitro Characterization of Cisplatin and Pemetrexed Effects in Malignant Pleural Mesothelioma 3D Culture Phenotypes
by: Eleftherios D. Papazoglou, et al.
Published: (2019-09-01)

Immune checkpoint inhibitors for unresectable malignant pleural mesothelioma
by: Giulio Metro, et al.
Published: (2021-09-01)

Pemetrexed-loaded nanoparticles targeted to malignant pleural mesothelioma cells: an in vitro study
by: Cova E, et al.
Published: (2019-01-01)

Phase 1 study of HSP90 inhibitor ganetespib with pemetrexed and cisplatin/carboplatin chemotherapy for pleural mesothelioma
by: Fennell, D, et al.
Published: (2018)

Pemetrexed disodium for the treatment of malignant pleural mesothelioma: a systematic review and economic evaluation
by: Y Dundar, et al.
Published: (2007-01-01)

Computed Tomography and Spirometry Can Predict Unresectability in Malignant Pleural Mesothelioma
by: Alice Bellini, et al.
Published: (2021-09-01)

Analysis of expression of programmed cell death 1 ligand 1 (PD-L1) in malignant pleural mesothelioma (MPM).
by: Susana Cedrés, et al.
Published: (2015-01-01)

A single centre phase II trial to assess the immunological activity of TroVax® plus pemetrexed/cisplatin in patients with malignant pleural mesothelioma – the SKOPOS trial
by: Jason F Lester, et al.
Published: (2018-12-01)

Alvopem® (pemetrexed) safety assessment in patients with non-small cell lung cancer or malignant pleural mesothelioma: a post-marketing surveillance
by: Sharareh Seifi, et al.
Published: (2023-01-01)

Interferon-β produces synergistic combinatory anti-tumor effects with cisplatin or pemetrexed on mesothelioma cells.
by: Quanhai Li, et al.
Published: (2013-01-01)

Efficacy, Safety, and Cost-Minimization Analysis of Continuous Infusion of Low-Dose Gemcitabine Plus Cisplatin in Patients With Unresectable Malignant Pleural Mesothelioma
by: Oscar Arrieta, et al.
Published: (2021-04-01)

Augmented expression of cardiac ankyrin repeat protein is induced by pemetrexed and a possible marker for the pemetrexed resistance in mesothelioma cells
by: Yiyang Qin, et al.
Published: (2017-12-01)

Re-challenge with pemetrexed in advanced mesothelioma: a multi-institutional experience
by: Bearz Alessandra, et al.
Published: (2012-09-01)

Malignant pleural mesothelioma
by: Rao Sukhesh
Published: (2009-01-01)

Cost-effectiveness analysis of nivolumab plus ipilimumab chemotherapy as the first-line treatment for unresectable malignant pleural mesothelioma
by: Liu Yang, et al.
Published: (2022-08-01)

Cost-effectiveness of nivolumab plus ipilimumab as first-line treatment for American patients with unresectable malignant pleural mesothelioma
by: Zhuo-miao Ye, et al.
Published: (2022-07-01)

Malignant pleural mesothelioma with resolution of pleural effusion
by: Sayaka Nishida, et al.
Published: (2023-11-01)

Pleural Mesothelioma: Advances in Blood and Pleural Biomarkers
by: Claudio Sorino, et al.
Published: (2023-11-01)

Response to Immune Checkpoint Inhibitor Therapy in Patients with Unresectable Recurrent Malignant Pleural Mesothelioma Shown by FDG-PET and CT
by: Kazuhiro Kitajima, et al.
Published: (2021-03-01)

Molecular resistance fingerprint of pemetrexed and platinum in a long-term survivor of mesothelioma.
by: Oluf Dimitri Røe, et al.
Published: (2012-01-01)

Cisplatin and Pemetrexed Activate AXL and AXL Inhibitor BGB324 Enhances Mesothelioma Cell Death from Chemotherapy
by: Derek B. Oien, et al.
Published: (2018-01-01)

Pleural mesothelioma metastasis of the scalp
by: Tugcem Bicak, et al.
Published: (2024-02-01)

Pleural Mesothelioma in the Era of Immunotherapy
by: Mathieu Chevallier, et al.
Published: (2023-07-01)

Extrathoracic Metastases in Pleural Mesothelioma
by: Ibiayi Dagogo-Jack, MD, et al.
Published: (2023-09-01)

Immunotherapy in Malignant Pleural Mesothelioma
by: Cornedine J. de Gooijer, et al.
Published: (2020-02-01)

Malignant pleural mesothelioma: an update
by: Glaucia N. M. Hajj, et al.
Published: (2021-12-01)

Current State-of-the-Art Therapy for Malignant Pleural Mesothelioma and Future Options Centered on Immunotherapy
by: Susana Cedres, et al.
Published: (2023-12-01)

Ranpirnase and its potential for the treatment of unresectable malignant mesothelioma
by: Camillo Porta, et al.
Published: (2008-08-01)

The association between pleural fluid exposure and survival in pleural mesothelioma
by: Asciak, R, et al.
Published: (2021)

Pleural abnormalities predating the development of mesothelioma
by: Hassan, M, et al.
Published: (2017)

Sarcopenia and Pleural Mesothelioma: The Current Knowledge
by: Nikolaos D. Karakousis, et al.
Published: (2024-02-01)